FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020150466> ?p ?o ?g. }

• W2020150466 endingPage "353" @default.
• W2020150466 startingPage "339" @default.
• W2020150466 abstract "Despite the significant successes in the area of anti-HBV agents, resistance and cross-resistance against available therapeutics are the major hurdles in drug discovery. The present investigation is to understand the molecular basis of drug resistance conferred by the B and C domain mutations of HBV-polymerase on the binding affinity of five anti-HBV agents [lamivudine (3TC, 1), adefovir (ADV, 2), entecavir (ETV, 3), telbivudine (LdT, 4) and clevudine (l-FMAU, 5)]. In this regard, homology modeled structure of HBV-polymerase was used for minimization, conformational search and induced fit docking followed by binding energy calculation on wild-type as well as on mutant HBV-polymerases (L180M, M204V, M204I, L180M + M204V, L180M − M204I). Our studies suggest a significant correlation between the fold resistances and the binding affinity of anti-HBV nucleosides. The binding mode studies reveals that the domain C residue M204 is closely associated with sugar/pseudosugar ring positioning in the active site. The positioning of oxathiolane ring of 3TC (1) is plausible due the induced fit orientation of the M204 residue in wild-type, and further mutation of M204 to V204 or I204 reduces the final binding affinity which leads to the drug resistance. The domain B residue L180 is not directly close (∼6 Å) to the nucleoside/nucleoside analogs, but indirectly associated with other active-site hydrophobic residues such as A87, F88, P177 and M204. These five hydrophobic residues can directly affect on the incoming nucleoside analogs in terms of its association and interaction that can alter the final binding affinity. There was no sugar ring shifting observed in the case of adefovir (2) and entecavir (3), and the position of sugar ring of 2 and 3 is found similar to the sugar position of natural substrate dATP and dGTP, respectively. The exocyclic double bond of entecavir (3) occupied in the backside hydrophobic pocket (made by residues A87, F88, P177, L180 and M204), which enhances the overall binding affinity. The active site binding of LdT (4) and l-FMAU (5) showed backward shifting along with upward movement without enforcing M204 residue and this significant different binding mode makes these molecules as polymerase inhibitors, without being incorporated into the growing HBV-DNA chain. Structural results conferred by these l- and d-nucleosides, explored the molecular basis of drug resistance which can be utilized for future anti-HBV drug discovery." @default.
• W2020150466 created "2016-06-24" @default.
• W2020150466 creator A5026934981 @default.
• W2020150466 creator A5078077421 @default.
• W2020150466 date "2008-12-01" @default.
• W2020150466 modified "2023-09-26" @default.
• W2020150466 title "Understanding the molecular basis of HBV drug resistance by molecular modeling" @default.
• W2020150466 cites W1582561043 @default.
• W2020150466 cites W1639652471 @default.
• W2020150466 cites W175035592 @default.
• W2020150466 cites W1932632320 @default.
• W2020150466 cites W1963997188 @default.
• W2020150466 cites W1973711348 @default.
• W2020150466 cites W1975691556 @default.
• W2020150466 cites W1977202875 @default.
• W2020150466 cites W1977368515 @default.
• W2020150466 cites W1979213644 @default.
• W2020150466 cites W1982960788 @default.
• W2020150466 cites W1985577568 @default.
• W2020150466 cites W1990627326 @default.
• W2020150466 cites W2006698257 @default.
• W2020150466 cites W2009423060 @default.
• W2020150466 cites W2014837723 @default.
• W2020150466 cites W2029689089 @default.
• W2020150466 cites W2037901246 @default.
• W2020150466 cites W2038767538 @default.
• W2020150466 cites W2042692189 @default.
• W2020150466 cites W2044824756 @default.
• W2020150466 cites W2052700689 @default.
• W2020150466 cites W2061505027 @default.
• W2020150466 cites W2069064401 @default.
• W2020150466 cites W2087871271 @default.
• W2020150466 cites W2091469139 @default.
• W2020150466 cites W2094608386 @default.
• W2020150466 cites W2095855829 @default.
• W2020150466 cites W2098723186 @default.
• W2020150466 cites W2103356635 @default.
• W2020150466 cites W2107057287 @default.
• W2020150466 cites W2114392718 @default.
• W2020150466 cites W2117181252 @default.
• W2020150466 cites W2120263884 @default.
• W2020150466 cites W2126563189 @default.
• W2020150466 cites W2137544368 @default.
• W2020150466 cites W2142861964 @default.
• W2020150466 cites W2143375642 @default.
• W2020150466 cites W2145285067 @default.
• W2020150466 cites W2147528958 @default.
• W2020150466 cites W2148987208 @default.
• W2020150466 cites W2152648191 @default.
• W2020150466 cites W2155154284 @default.
• W2020150466 cites W2155917911 @default.
• W2020150466 cites W2156688847 @default.
• W2020150466 cites W2158375882 @default.
• W2020150466 cites W2160625239 @default.
• W2020150466 cites W2164896443 @default.
• W2020150466 cites W2165407652 @default.
• W2020150466 cites W2323719395 @default.
• W2020150466 cites W2433440716 @default.
• W2020150466 cites W2769990393 @default.
• W2020150466 cites W3009157329 @default.
• W2020150466 cites W72142418 @default.
• W2020150466 doi "https://doi.org/10.1016/j.antiviral.2008.07.010" @default.
• W2020150466 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2626186" @default.
• W2020150466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18765256" @default.
• W2020150466 hasPublicationYear "2008" @default.
• W2020150466 type Work @default.
• W2020150466 sameAs 2020150466 @default.
• W2020150466 citedByCount "34" @default.
• W2020150466 countsByYear W20201504662012 @default.
• W2020150466 countsByYear W20201504662013 @default.
• W2020150466 countsByYear W20201504662014 @default.
• W2020150466 countsByYear W20201504662015 @default.
• W2020150466 countsByYear W20201504662016 @default.
• W2020150466 countsByYear W20201504662017 @default.
• W2020150466 countsByYear W20201504662018 @default.
• W2020150466 countsByYear W20201504662019 @default.
• W2020150466 countsByYear W20201504662020 @default.
• W2020150466 countsByYear W20201504662021 @default.
• W2020150466 crossrefType "journal-article" @default.
• W2020150466 hasAuthorship W2020150466A5026934981 @default.
• W2020150466 hasAuthorship W2020150466A5078077421 @default.
• W2020150466 hasBestOaLocation W20201504662 @default.
• W2020150466 hasConcept C107824862 @default.
• W2020150466 hasConcept C159047783 @default.
• W2020150466 hasConcept C159110408 @default.
• W2020150466 hasConcept C169627665 @default.
• W2020150466 hasConcept C181199279 @default.
• W2020150466 hasConcept C185592680 @default.
• W2020150466 hasConcept C2522874641 @default.
• W2020150466 hasConcept C2776175608 @default.
• W2020150466 hasConcept C2776543447 @default.
• W2020150466 hasConcept C2777333352 @default.
• W2020150466 hasConcept C2777869810 @default.
• W2020150466 hasConcept C2779517838 @default.
• W2020150466 hasConcept C2780593183 @default.
• W2020150466 hasConcept C2781144229 @default.
• W2020150466 hasConcept C41685203 @default.
• W2020150466 hasConcept C552990157 @default.

• next